RU2487873C2 - 5-замещенные индазолы в качестве ингибиторов киназы - Google Patents
5-замещенные индазолы в качестве ингибиторов киназы Download PDFInfo
- Publication number
- RU2487873C2 RU2487873C2 RU2009149696/04A RU2009149696A RU2487873C2 RU 2487873 C2 RU2487873 C2 RU 2487873C2 RU 2009149696/04 A RU2009149696/04 A RU 2009149696/04A RU 2009149696 A RU2009149696 A RU 2009149696A RU 2487873 C2 RU2487873 C2 RU 2487873C2
- Authority
- RU
- Russia
- Prior art keywords
- indazol
- triazol
- carboxamide
- benzyl
- indazole
- Prior art date
Links
- 0 C*C1C=CC(*)C1C Chemical compound C*C1C=CC(*)C1C 0.000 description 10
- HMYHIKAXGAPRJL-UHFFFAOYSA-N C#Cc(cc1)cc(C#N)c1F Chemical compound C#Cc(cc1)cc(C#N)c1F HMYHIKAXGAPRJL-UHFFFAOYSA-N 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N CC(C)CCON=O Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- OOMAOWASFMLDOS-UHFFFAOYSA-N CC([n]1ncc2cc(-[n]3nnc(C)c3)ccc12)=O Chemical compound CC([n]1ncc2cc(-[n]3nnc(C)c3)ccc12)=O OOMAOWASFMLDOS-UHFFFAOYSA-N 0.000 description 1
- JNWIBFFQBLTCMJ-UHFFFAOYSA-N CC([n]1ncc2cc(I)ccc12)=O Chemical compound CC([n]1ncc2cc(I)ccc12)=O JNWIBFFQBLTCMJ-UHFFFAOYSA-N 0.000 description 1
- BGKLFAQCHHCZRZ-UHFFFAOYSA-N Cc(cc(cc1)I)c1N Chemical compound Cc(cc(cc1)I)c1N BGKLFAQCHHCZRZ-UHFFFAOYSA-N 0.000 description 1
- CMAOLVNGLTWICC-UHFFFAOYSA-N Cc(cc1C#N)ccc1F Chemical compound Cc(cc1C#N)ccc1F CMAOLVNGLTWICC-UHFFFAOYSA-N 0.000 description 1
- NGIUTERFVXJARU-UHFFFAOYSA-N N#Cc1cc(-c2c[nH]nn2)ccc1F Chemical compound N#Cc1cc(-c2c[nH]nn2)ccc1F NGIUTERFVXJARU-UHFFFAOYSA-N 0.000 description 1
- BIZHQRAAZMDWNK-UHFFFAOYSA-N N#Cc1cc(I)ccc1F Chemical compound N#Cc1cc(I)ccc1F BIZHQRAAZMDWNK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93396007P | 2007-06-08 | 2007-06-08 | |
US60/933,960 | 2007-06-08 | ||
PCT/US2008/065727 WO2008154241A1 (fr) | 2007-06-08 | 2008-06-04 | Indazoles à substitution 5-hétéroaryle servant d'inhibiteurs de kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2009149696A RU2009149696A (ru) | 2011-07-20 |
RU2487873C2 true RU2487873C2 (ru) | 2013-07-20 |
Family
ID=39951673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2009149696/04A RU2487873C2 (ru) | 2007-06-08 | 2008-06-04 | 5-замещенные индазолы в качестве ингибиторов киназы |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP2167491A1 (fr) |
JP (2) | JP5451602B2 (fr) |
KR (1) | KR20100032886A (fr) |
CN (1) | CN101790526A (fr) |
AU (1) | AU2008262038A1 (fr) |
BR (1) | BRPI0811065A2 (fr) |
CA (1) | CA2689117A1 (fr) |
IL (1) | IL202318A0 (fr) |
MX (1) | MX2009013213A (fr) |
RU (1) | RU2487873C2 (fr) |
SG (1) | SG182187A1 (fr) |
WO (1) | WO2008154241A1 (fr) |
ZA (1) | ZA200908624B (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2725979C2 (ru) * | 2014-06-25 | 2020-07-08 | Ф. Хоффманн-Ля Рош Аг | ИМИДАЗО[1,2-а]ПИРАЗИН-1-ИЛ-БЕНЗАМИДЫ ДЛЯ ЛЕЧЕНИЯ СПИНАЛЬНОЙ МЫШЕЧНОЙ АТРОФИИ |
US10899742B1 (en) | 2016-12-01 | 2021-01-26 | Arvinas Operations, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
Families Citing this family (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
EP1984331B1 (fr) | 2006-02-16 | 2010-10-20 | Schering Corporation | Dérivés de pyrrolidine comme inhibiteurs de la erk |
US8648069B2 (en) * | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
US20110301155A1 (en) * | 2007-06-19 | 2011-12-08 | Tsuneo Yasuma | Indazole compounds for activating glucokinase |
EP2173728A2 (fr) | 2007-07-17 | 2010-04-14 | Amgen Inc. | Modulateurs hétérocycliques de pkb |
CA2693473A1 (fr) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazoles modulateurs de l'activite de pkb |
KR20100046275A (ko) * | 2007-08-30 | 2010-05-06 | 다케다 야쿠힌 고교 가부시키가이샤 | 치환 피라졸 유도체 |
US8716483B2 (en) | 2008-02-21 | 2014-05-06 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
CL2009001158A1 (es) * | 2008-05-15 | 2009-10-23 | Nerviano Medical Sciences Srl | Compuestos derivados de los acidos carboxilicos, tales como 5,6-dihiro-4h-pirrolo[3,4-c]pirazol, furo[3,2-c]pirazol, tieno[2,3-c]pirazol, 4,5,6,7-tetrahidropirazol[4,3-c]piridina e indazol; composicion farmaceutica; y su uso en el tratamiento de trastornos proliferativos celulares asociados a la actividad de proteina quinasa alterada, tal como el cancer. |
WO2010059658A1 (fr) * | 2008-11-20 | 2010-05-27 | Glaxosmithkline Llc | Composés chimiques |
HUE028259T2 (en) | 2009-08-10 | 2016-12-28 | Samumed Llc | Inhibitors of Wnt signaling signal indazole and their therapeutic use |
JP5822844B2 (ja) | 2009-12-21 | 2015-11-24 | サミュメッド リミテッド ライアビリティ カンパニー | 1H−ピラゾロ[3,4−b]ピリジンおよびその治療的使用 |
UY33213A (es) * | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
KR101233082B1 (ko) | 2010-02-25 | 2013-02-14 | 주식회사 이큐스앤자루 | 신규한 이미다졸피라진 유도체 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 항바이러스 치료용 약학적 조성물 |
EP2542549B1 (fr) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Inhibiteurs de glutaminyl cyclase |
TW201144310A (en) * | 2010-04-28 | 2011-12-16 | Daiichi Sankyo Co Ltd | [5,6] heterocyclic compound |
EP2566333A4 (fr) * | 2010-05-07 | 2014-04-02 | Univ Leland Stanford Junior | Identification de stabilisants de protéines multimériques |
ES2592713T3 (es) | 2010-12-20 | 2016-12-01 | Merck Serono S.A. | Derivados de indazolil-triazol como inhibidores de IRAK |
WO2012087833A1 (fr) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Inhibiteurs de l'hépatite c et leurs utilisations |
US9090592B2 (en) * | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
CN102675286B (zh) * | 2011-03-07 | 2015-08-19 | 中国科学院上海药物研究所 | 一类吲唑类化合物及其制备方法、用途和药物组合物 |
HUE026323T2 (en) * | 2011-04-07 | 2016-05-30 | Bayer Ip Gmbh | Imidazopyridazines as AKT kinase inhibitors |
KR20140071361A (ko) * | 2011-08-12 | 2014-06-11 | 에프. 호프만-라 로슈 아게 | 피라졸로[3,4-c]피리딘 화합물 및 사용 방법 |
IN2014CN02646A (fr) | 2011-09-14 | 2015-08-07 | Samumed Llc | |
DK2921492T3 (en) | 2011-12-27 | 2017-12-11 | Bayer Ip Gmbh | HETEROARYLPIPERIDINE AND ¿PIPERAZINE DERIVATIVES |
BR112014018655B1 (pt) * | 2012-02-21 | 2022-02-08 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A | Composto de 1h-indazol-3-carboxamida, e, composição farmacêutica |
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
NZ724837A (en) | 2012-05-04 | 2018-05-25 | Samumed Llc | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
TW201406758A (zh) * | 2012-06-28 | 2014-02-16 | Daiichi Sankyo Co Ltd | 三環性化合物 |
MX370487B (es) | 2013-01-08 | 2019-12-16 | Samumed Llc | Inhibidores de 3-(benzo-imidazol-2-il)-indazol de la senda de señalización de wnt y usos terapéuticos de los mismos. |
WO2014137728A1 (fr) | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Composés inhibant l'activité enzymatique de la kinase à répétition riche en leucine |
WO2014134772A1 (fr) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine |
WO2014134774A1 (fr) | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine |
WO2014134776A1 (fr) | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine |
JO3383B1 (ar) * | 2013-03-14 | 2019-03-13 | Lilly Co Eli | مثبطات cdc7 |
JP6461118B2 (ja) * | 2013-06-21 | 2019-01-30 | ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. | ブロモドメイン阻害剤としての新規の置換された二環式化合物 |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
ES2901711T3 (es) | 2014-02-13 | 2022-03-23 | Incyte Corp | Ciclopropilaminas como inhibidores de LSD1 |
ME03580B (fr) | 2014-02-13 | 2020-07-20 | Incyte Corp | Cyclopropylamines en tant qu'inhibiteurs de lsd1 |
EP3105219B9 (fr) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines en tant qu'inhibiteurs de lsd1 |
SG10201914111XA (en) | 2014-03-20 | 2020-03-30 | Samumed Llc | 5-substituted indazole-3-carboxamides and preparation and use thereof |
WO2015143652A1 (fr) * | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | Inhibiteurs de la kinase trka, compositions et méthodes associées |
WO2016007727A1 (fr) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1 |
WO2016007731A1 (fr) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines et imidazopyrazines à utiliser en tant qu'inhibiteurs de lsd1 |
WO2016007722A1 (fr) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1 |
US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
US20160045609A1 (en) | 2014-08-14 | 2016-02-18 | Mamoun M. Alhamadsheh | Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life |
WO2016040180A1 (fr) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques |
WO2016040188A1 (fr) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques |
WO2016040181A1 (fr) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques |
WO2016040184A1 (fr) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques |
WO2016040193A1 (fr) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine et ses utilisations thérapeutiques |
WO2016040190A1 (fr) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine et ses utilisations thérapeutiques |
WO2016040185A1 (fr) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine et ses utilisations thérapeutiques |
WO2016040182A1 (fr) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine et ses utilisations thérapeutiques |
EA037112B1 (ru) * | 2015-03-02 | 2021-02-08 | Ригель Фармасьютикалс, Инк. | Ингибиторы tgf- |
SG11201708047UA (en) | 2015-04-03 | 2017-10-30 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors |
US10383861B2 (en) | 2015-08-03 | 2019-08-20 | Sammumed, LLC | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
WO2017024004A1 (fr) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques |
US10195185B2 (en) | 2015-08-03 | 2019-02-05 | Samumed, Llc | 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
WO2017023996A1 (fr) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines et leurs utilisations thérapeutiques |
WO2017024021A1 (fr) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles et leurs utilisations thérapeutiques |
US10166218B2 (en) | 2015-08-03 | 2019-01-01 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
US10519169B2 (en) | 2015-08-03 | 2019-12-31 | Samumed, Llc | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
WO2017023993A1 (fr) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques |
WO2017024003A1 (fr) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques |
WO2017024015A1 (fr) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques |
US10604512B2 (en) | 2015-08-03 | 2020-03-31 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof |
WO2017023984A1 (fr) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines et leurs utilisations thérapeutiques |
US10285982B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
WO2017023987A1 (fr) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines et leurs utilisations thérapeutiques |
US10392383B2 (en) | 2015-08-03 | 2019-08-27 | Samumed, Llc | 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10463651B2 (en) | 2015-08-03 | 2019-11-05 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof |
US10188634B2 (en) | 2015-08-03 | 2019-01-29 | Samumed, Llc | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
MY189367A (en) | 2015-08-12 | 2022-02-08 | Incyte Corp | Salts of an lsd1 inhibitor |
WO2017079759A1 (fr) | 2015-11-06 | 2017-05-11 | Samumed, Llc | 2-(3h-indazol-3-yl)-1h-imidazo[4,5-c]pyridines et leurs utilisations anti-inflammatoires |
US20170273307A1 (en) * | 2016-03-28 | 2017-09-28 | Trent University | Silane-based antimicrobial coatings and methods of making and using the same |
AR109452A1 (es) | 2016-04-22 | 2018-12-12 | Incyte Corp | Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento |
HRP20221446T1 (hr) | 2016-06-01 | 2023-01-06 | Biosplice Therapeutics, Inc. | Postupci za pripremu n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida |
WO2018053588A1 (fr) | 2016-09-21 | 2018-03-29 | Vectus Biosystems Limited | Compositions pour le traitement de l'hypertension et/ou de la fibrose |
EA038510B1 (ru) | 2016-09-23 | 2021-09-08 | Новартис Аг | Индазольные соединения для применения при повреждениях сухожилий и/или связок |
JOP20190053A1 (ar) | 2016-09-23 | 2019-03-21 | Novartis Ag | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |
BR112019008061A2 (pt) | 2016-10-21 | 2019-09-17 | Samumed Llc | métodos de uso de indazol-3-carboxamidas e seu uso como inibidores da via de sinalização de wnt/b-catenina |
JP2019533702A (ja) | 2016-11-07 | 2019-11-21 | サミュメッド リミテッド ライアビリティ カンパニー | 単回用量の調整済み注射用製剤 |
IL268683B2 (en) | 2017-02-17 | 2023-04-01 | Eidos Therapeutics Inc | Processes for the preparation of ag-10, its intermediates and salts |
CA3063616A1 (fr) | 2017-06-30 | 2019-12-06 | Beijing Tide Pharmaceutical Co., Ltd. | Inhibiteur de proteine kinase associee a rho, composition pharmaceutique le comprenant, son procede de preparation et son utilisation |
WO2019000682A1 (fr) * | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Inhibiteur de protéine kinase associée à rho, composition pharmaceutique contenant celui-ci, son procédé de préparation et ses applications |
CN112004817B (zh) | 2018-02-15 | 2023-06-23 | 弗特克斯药品有限公司 | 作为cftr的调节剂的大环化合物、其药物组合物、它们的用途和制备方法 |
JP2021518381A (ja) | 2018-03-23 | 2021-08-02 | エイドス セラピューティクス,インコーポレイティド | Ag10を使用するttrアミロイドーシスの治療方法 |
JP7187575B2 (ja) * | 2018-04-18 | 2022-12-12 | メッドシャイン ディスカバリー インコーポレイテッド | Rhoキナーゼ阻害剤としてのベンゾピラゾール系化合物 |
KR20210046708A (ko) | 2018-08-17 | 2021-04-28 | 에이도스 테라퓨틱스, 인코포레이티드 | Ag10의 제형 |
WO2020047198A1 (fr) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Sels d'un inhibiteur de lsd1 et leurs procédés de préparation |
CN111138426B (zh) * | 2018-11-02 | 2023-03-10 | 安徽中科拓苒药物科学研究有限公司 | 吲唑类激酶抑制剂及其用途 |
US20220133740A1 (en) | 2019-02-08 | 2022-05-05 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
CN110218694A (zh) * | 2019-05-30 | 2019-09-10 | 华中农业大学 | 一种猕猴桃果实淀粉体提取方法 |
CN114599657A (zh) | 2019-08-14 | 2022-06-07 | 弗特克斯药品有限公司 | Cftr调节剂的结晶形式 |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
CN111171023B (zh) * | 2020-01-10 | 2021-12-21 | 中国药科大学 | 一种具有Pim1抑制活性的化合物及其制备方法与医药用途 |
CN113350347B (zh) * | 2020-03-05 | 2023-07-04 | 安徽中科拓苒药物科学研究有限公司 | 吲唑类化合物的用途 |
WO2022015979A1 (fr) * | 2020-07-15 | 2022-01-20 | Ifm Due, Inc. | Composés et compositions pour traiter des états pathologiques associés à une activité de sting |
US20230373974A1 (en) * | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
CN112266378B (zh) * | 2020-11-09 | 2021-10-12 | 延边大学 | 含吲唑结构的咪唑类衍生物及其制备方法和应用 |
CN113336759B (zh) * | 2020-12-25 | 2022-12-06 | 中国药科大学 | 溴结构域蛋白4小分子抑制剂、其制备方法及应用 |
EP4274824A1 (fr) * | 2021-01-08 | 2023-11-15 | IFM Due, Inc. | Composés hétérobicycliques ayant une urée ou un analogue et leurs compositions pour le traitement d'états associés à une activité de sting |
KR20230056824A (ko) * | 2021-10-20 | 2023-04-28 | 전북대학교산학협력단 | Pak4 저해제 및 그의 용도 |
WO2023186773A1 (fr) | 2022-03-30 | 2023-10-05 | Nerviano Medical Sciences S.R.L. | Dérivés de 3-amino indazole substitués utilisés en tant qu'inhibiteurs de kinase |
CN114651898B (zh) * | 2022-03-31 | 2024-04-05 | 天津溢佳同惠科技集团有限公司 | 一种提高免疫力的三唑类饲料添加剂及其制备方法和应用 |
WO2023218201A1 (fr) * | 2022-05-11 | 2023-11-16 | Cancer Research Technology Limited | Inhibiteurs d'ikk |
KR102607237B1 (ko) * | 2023-06-07 | 2023-11-30 | 주식회사 젠센 | 신규한 트리아졸이 치환된 인다졸 유도체 및 이의 용도 |
CN116891460A (zh) * | 2023-07-12 | 2023-10-17 | 浙江大学 | 一种吲唑类衍生物或其药用盐及应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001053268A2 (fr) * | 2000-01-18 | 2001-07-26 | Agouron Pharmaceuticals, Inc. | Composes d'indazole, compositions pharmaceutiques, et methodes destines a la mediation ou a l'inhibition de la proliferation cellulaire |
WO2004013410A1 (fr) * | 2002-08-06 | 2004-02-12 | Richard Stone | Toile de formation composite a triplets de chaines |
WO2004031158A1 (fr) * | 2002-10-02 | 2004-04-15 | Sanofi-Aventis | Derives d'indazolecarboxamides, leur preparation et leur utilisation comme inhibiteurs des cdk1, cdk2 et cdk4 |
WO2004039325A2 (fr) * | 2002-10-24 | 2004-05-13 | Celgene Corporation | Compositions contenant un inhibiteur de jnk destinees a traiter, prevenir, gerer et/ou modifier la douleur, et leurs methodes d'utilisation |
WO2005009997A1 (fr) * | 2003-07-30 | 2005-02-03 | Pfizer Inc. | Composes d'indazole 3,5 disubstitutes, compositions pharmaceutiques, et procedes pour medier ou inhiber la proliferation cellulaire |
US20050090529A1 (en) * | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
WO2005099703A1 (fr) * | 2004-03-16 | 2005-10-27 | Sanofi-Aventis | Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme |
RU2005121897A (ru) * | 2002-12-12 | 2006-01-20 | Авентис Фарма С.А. (Fr) | Производные аминоиндазолов и их применение в качестве ингибиторов киназ |
WO2006130297A2 (fr) * | 2005-04-29 | 2006-12-07 | Celgene Corporation | Formes solides d'in inhibiteur jnk |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7211594B2 (en) * | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
JP2004528295A (ja) * | 2001-01-30 | 2004-09-16 | サイトピア ピーティワイ リミテッド | キナーゼ阻害方法 |
CN101037438A (zh) * | 2002-08-02 | 2007-09-19 | 沃泰克斯药物股份有限公司 | 用作gsk-3的抑制剂的吡唑组合物 |
EP1708697A4 (fr) * | 2004-01-30 | 2007-11-28 | Smithkline Beecham Corp | Composes chimiques |
ATE487716T1 (de) * | 2004-04-22 | 2010-11-15 | Memory Pharm Corp | Indole, 1h-indazole, 1,2-benzisoxazole, 1,2- benzoisothiazole, deren herstellung und verwendungen |
DE102004028862A1 (de) * | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
US7429604B2 (en) * | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
JP2008503591A (ja) * | 2004-06-22 | 2008-02-07 | ライジェル ファーマシューティカルズ, インコーポレイテッド | ユビキチンリガーゼ阻害剤 |
ATE519488T1 (de) * | 2004-12-27 | 2011-08-15 | Novartis Ag | Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten |
JP2009515882A (ja) * | 2005-11-10 | 2009-04-16 | シェーリング コーポレイション | プロテインキナーゼを阻害するための方法 |
US8008481B2 (en) * | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
-
2008
- 2008-06-04 MX MX2009013213A patent/MX2009013213A/es not_active Application Discontinuation
- 2008-06-04 KR KR1020107000409A patent/KR20100032886A/ko not_active Application Discontinuation
- 2008-06-04 BR BRPI0811065-4A2A patent/BRPI0811065A2/pt not_active IP Right Cessation
- 2008-06-04 CN CN200880102038A patent/CN101790526A/zh active Pending
- 2008-06-04 EP EP08770094A patent/EP2167491A1/fr not_active Withdrawn
- 2008-06-04 CA CA002689117A patent/CA2689117A1/fr not_active Abandoned
- 2008-06-04 AU AU2008262038A patent/AU2008262038A1/en not_active Abandoned
- 2008-06-04 RU RU2009149696/04A patent/RU2487873C2/ru not_active IP Right Cessation
- 2008-06-04 JP JP2010511293A patent/JP5451602B2/ja not_active Expired - Fee Related
- 2008-06-04 WO PCT/US2008/065727 patent/WO2008154241A1/fr active Application Filing
- 2008-06-04 SG SG2012043113A patent/SG182187A1/en unknown
-
2009
- 2009-11-24 IL IL202318A patent/IL202318A0/en unknown
- 2009-12-04 ZA ZA2009/08624A patent/ZA200908624B/en unknown
-
2013
- 2013-12-25 JP JP2013266989A patent/JP2014074057A/ja active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001053268A2 (fr) * | 2000-01-18 | 2001-07-26 | Agouron Pharmaceuticals, Inc. | Composes d'indazole, compositions pharmaceutiques, et methodes destines a la mediation ou a l'inhibition de la proliferation cellulaire |
WO2004013410A1 (fr) * | 2002-08-06 | 2004-02-12 | Richard Stone | Toile de formation composite a triplets de chaines |
WO2004031158A1 (fr) * | 2002-10-02 | 2004-04-15 | Sanofi-Aventis | Derives d'indazolecarboxamides, leur preparation et leur utilisation comme inhibiteurs des cdk1, cdk2 et cdk4 |
WO2004039325A2 (fr) * | 2002-10-24 | 2004-05-13 | Celgene Corporation | Compositions contenant un inhibiteur de jnk destinees a traiter, prevenir, gerer et/ou modifier la douleur, et leurs methodes d'utilisation |
RU2005121897A (ru) * | 2002-12-12 | 2006-01-20 | Авентис Фарма С.А. (Fr) | Производные аминоиндазолов и их применение в качестве ингибиторов киназ |
WO2005009997A1 (fr) * | 2003-07-30 | 2005-02-03 | Pfizer Inc. | Composes d'indazole 3,5 disubstitutes, compositions pharmaceutiques, et procedes pour medier ou inhiber la proliferation cellulaire |
US20050090529A1 (en) * | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
WO2005099703A1 (fr) * | 2004-03-16 | 2005-10-27 | Sanofi-Aventis | Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme |
WO2006130297A2 (fr) * | 2005-04-29 | 2006-12-07 | Celgene Corporation | Formes solides d'in inhibiteur jnk |
Non-Patent Citations (1)
Title |
---|
SHEELA A. THOMAS et al. Identification of a novel 3,5-disubstituted pyridine as potent, selective, and orally active inhibitor of Aktl kinase. Bioorganic & Medicinal Chemistry Letters. 2006, 16, p.3740-3744. * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2725979C2 (ru) * | 2014-06-25 | 2020-07-08 | Ф. Хоффманн-Ля Рош Аг | ИМИДАЗО[1,2-а]ПИРАЗИН-1-ИЛ-БЕНЗАМИДЫ ДЛЯ ЛЕЧЕНИЯ СПИНАЛЬНОЙ МЫШЕЧНОЙ АТРОФИИ |
US10899742B1 (en) | 2016-12-01 | 2021-01-26 | Arvinas Operations, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
RU2750484C2 (ru) * | 2016-12-01 | 2021-06-28 | Эрвинэс Оперейшнс, Инк. | Производные тетрагидронафталина и тетрагидроизохинолина в качестве разрушителей эстрогенового рецептора |
US11597720B2 (en) | 2016-12-01 | 2023-03-07 | Arvinas Operations, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
Also Published As
Publication number | Publication date |
---|---|
JP5451602B2 (ja) | 2014-03-26 |
CN101790526A (zh) | 2010-07-28 |
JP2014074057A (ja) | 2014-04-24 |
WO2008154241A1 (fr) | 2008-12-18 |
JP2010529137A (ja) | 2010-08-26 |
ZA200908624B (en) | 2015-08-26 |
IL202318A0 (en) | 2010-06-30 |
AU2008262038A1 (en) | 2008-12-18 |
BRPI0811065A2 (pt) | 2014-12-02 |
SG182187A1 (en) | 2012-07-30 |
CA2689117A1 (fr) | 2008-12-18 |
KR20100032886A (ko) | 2010-03-26 |
EP2167491A1 (fr) | 2010-03-31 |
MX2009013213A (es) | 2010-03-30 |
RU2009149696A (ru) | 2011-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2487873C2 (ru) | 5-замещенные индазолы в качестве ингибиторов киназы | |
US9163007B2 (en) | 5-substituted indazoles as kinase inhibitors | |
US11987560B2 (en) | Inhibitors of lysine specific demethylase-1 | |
JP6663866B2 (ja) | リジン特異的なデメチラーゼ−1の阻害剤 | |
US11891389B2 (en) | PGDH inhibitors and methods of making and using | |
DK2504333T3 (en) | Morpholinothiazoler which alpha-7 positive allosteric modulators | |
EP3813819A1 (fr) | Inhibiteurs de kinases dépendantes des cyclines | |
JP2019172676A (ja) | リジン特異的なデメチラーゼ−1の阻害剤 | |
EA025086B1 (ru) | Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний | |
AU2013361255A1 (en) | Histone demethylase inhibitors | |
AU2014298017B2 (en) | Heterobicycloaryl RORC2 inhibitors and methods of use thereof | |
JP2005530760A (ja) | プロテインキナーゼモジュレーターおよびその使用方法 | |
BRPI0713576A2 (pt) | composto, formulação farmacêutica, uso de um composto, e, métodos para prevenir e/ou tratar condição, distúrbio e doença, para aumentar a formação óssea, para aumentar a formação óssea de estrutura esponjosa e/ou nova formação óssea, para aumentar a densidade mineral óssea, para reduzir a incidência de fratura e para melhorar a cicatrização de fratura, e, processo para preparar um composto | |
DK2817302T3 (en) | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase-3 beta inhibitors | |
DK2817301T3 (en) | Use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase-3 beta inhibitors | |
JP2013533318A (ja) | ヘテロアリールおよびその使用 | |
KR20240102934A (ko) | 피롤로[2,3-b]피리딘 PGDH 억제제 그리고 제조 및 사용 방법 | |
AU2013231090A1 (en) | 5-heteroaryl substituted indazoles as kinase inhibitors | |
CA2959290A1 (fr) | Derive 2-aminothiazole ou sel de ce dernier |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC41 | Official registration of the transfer of exclusive right |
Effective date: 20141128 |
|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20150605 |